RudaCure与翰林制药签署150亿韩元干眼症治疗药RCI001开发与投资合同

Emerging 生物风投企业 RudaCure Inc. (CEO Yongho Kim) has signed a 联合研发 and investment agreement with 翰林制药 Co., Ltd. (CEO Jaeyoon Kim, Jeongjin Kim), a leading 制药公司 in 眼科 drugs, for the 干眼症治疗药 RCI001. RCI001, the contracted technology, is a drug that exerts powerful 抗炎和抗氧化效果 through a mechanism that suppresses 炎症激活, thereby alleviating 干眼症. 翰林制药 decided to pursue 联合研发 of this technology and invest in RudaCure after highly evaluating the commercialization potential of RCI001, based on its faster 泪液分泎, 角膜损伤恢复 capability, and superior 滴眼顺应性 and safety compared to commercially available competing drugs. The total contract value is KRW 15 billion, comprising a fixed licensing fee, separate milestone-based royalties, and investment funds. 翰林制药 will be responsible for process development, GMP production, and supply of RCI001, and will secure domestic sales rights and a certain equity stake in RudaCure. RudaCure will focus on 研发 including 国内外临床试验, as well as overseas licensing. RudaCure plans to leverage this partnership with 翰林制药 to accelerate its 管线 development and pursue global technology licensing, targeting successful commercialization of RCI001.

전자신문